Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT04737265

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 1/2
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04737265
Other papers using this trial's data
  • Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical Trial JAMA network open, 2025-12-01 DOI, PubMed 41335439, PMC12676363 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04737265. Randomized; no masking; primary purpose prevention. Start 2021-03-18 (actual); primary completion 2025-02-05 (actual). Results posted on 2026-06-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Acronym
NTproBNP-Guide
Condition
Cardiotoxicity
Condition
Toxicity Due to Chemotherapy
Condition
Breast Cancer
Condition
Lymphoma
Condition
Cardiomyopathies
Condition
Heart Failure
Intervention (Other)
Biomarker Guided Intervention
Lead sponsor
Abramson Cancer Center at Penn Medicine (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04737265
Content hash
6b77f80ceea3aa95fee29aa98a0d04f17363e757248eddfa43bc1c3d4f74061e